Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Sam Saberian , medically reviewed by Alen A
The popularity of GLP-1 drugs as a treatment for obesity meets a sobering reality of poor adherence and high cost of care in the real world, and it may be quite some time before these measures and health metrics improve in any substantial way. The latest report covers several key topics: Primes clinical position
Sehgal NK et al
biophysical Res
Wang Y, Qi H, Liu Y, Duan C, Liu X, Xia T, et al
A systematic review and meta-analysis published in Diabetes, Obesity and Metabolism examined cardiovascular outcome trials involving over 60,000 patients treated with GLP-1 receptor agonists
US$ 28.68
US$ 21.12
US$ 20.55
